An open-label phase II trial of motexafin gadolinium (MGd) in patients with relapsed or refractory multiple myeloma
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Motexafin gadolinium (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Pharmacyclics
- 02 Nov 2016 Last checked against ClinicalTrials.gov record.
- 07 Jun 2007 Status changed from recruiting to completed.
- 26 Aug 2005 New trial record.